#asxstock
Text
Fintip: Empowering ASX Share Investors for Success
Fintip is a comprehensive platform designed to empower ASX share investors with the knowledge, tools, and insights they need to achieve success in the Australian Securities Exchange (ASX) market. With Fintip, you can explore a world of opportunities, make informed investment decisions, and stay ahead of market trends.
0 notes
Text
The 10 Most Expensive Stocks on the Australian Securities Exchange
#asx #asxstocks #australianstocks #mostexpensivestocks #Stocks
0 notes
Text
Top 5 ASX 200 Healthcare Stocks for 2022
ASX 200 healthcare stocks had a spectacular bull run at the onset of the COVID-19 pandemic. Most healthcare stocks appreciated significantly in the last two years. However, the bull run for healthcare stocks is not over. The pandemic showed the under-preparedness of the healthcare sectors of most countries to deal with a healthcare crisis of such a scale. Therefore, we expect a significant increase in healthcare spending, which will continue to benefit healthcare and pharma companies.
Healthcare is an important defensive sector along with utilities and consumer goods. Investing a portion of total investible funds in defensive sector like healthcare is a good hedge against inflation. Also, defensive sector investment can lower the overall risk of the portfolio. An ideal portfolio, therefore, should include both growth as well as defensive sectors in the right mix. Healthcare is probably the most important defensive sector as healthcare spending is not affected much even if there is an economic downturn.
The healthcare sector as a whole is going through a re-rating which reflects its long-term potential. According to estimations, earnings of the ASX 200 healthcare companies are expected to grow by 14% annually in the next few years. With expected economic recoveries and higher healthcare spending across the world, we remain bullish on the healthcare sector.
Here are our top five ASX 200 healthcare stocks for 2023.
1. CSL Limited (ASX: CSL)
About the company
Commonwealth Serum Laboratories (CSL) is a leading healthcare company in Australia. It has a wide portfolio of businesses serving all healthcare verticals. CSL Behring is a global leader in dealing with rare and serious diseases. CSL Seqirus is a major influenza vaccine supplier in the world. CSL Plasma is the world's largest plasma collection company. The most recent division CSL Vifor deals with iron deficiency and nephrology. The company has a current market capitalization of $142.13 billion.
Stock Information
The previous closing price of the stock was $293.7. It is currently trading at a PE ratio of 41.24. Its current earnings per share are $5.08. The stock is currently trading at an attractive valuation as it has corrected by 5.33% in the last 1 year. However, the stock has outperformed the entire pharma sector by 5.63% in the same period. This reflects the relative attractiveness of the stock compared to its peers.
The company posted a full-year profit of $2.25 billion, which was in line with Bloomberg estimates of US$2.26bn and better than Morgan Stanley’s forecasts of US$2.18bn. The company anticipates strong growth in plasma collections and plasma therapies. The guidance for net profit after tax in FY23 is US$2.4 billion to US$2.5 billion, which means a growth of around 6.5% to 11%.
2. Mayne Pharma (ASX: MYX)
About the company
Mayne is an ASX-listed specialty pharma company that commercializes branded and generic drugs. In the last 40 years, the company has developed new oral drug delivery systems and commercialized numerous products around the world.
The primary business of Mayne is developing and manufacturing proprietary and generic pharmaceuticals. It has two main development and manufacturing centers based in Salisbury, Australia, and Greenville, North Carolina, US. Mayne specializes in various complex oral dosage forms such as potent compounds, modified-release products, and poorly soluble compounds.
The company has a current market cap of $469,750,187
Stock Information
The previous closing price of the stock was $0.27. The stock has corrected significantly in the last 1 year. It is currently trading at 15.6% lower as compared to 1 year before. This makes the current valuation of the stock very attractive for long-term investors.
The company reported revenues of $424.8m, up 6% from FY21. It also reported a 40% increase in its branded products revenue. The company is expected to get a substantial amount of cash injection after agreeing to sell its Metrics Contract Services business to Catalent for US$475 million.
3. Clinuvel Pharmaceuticals (ASX: CUV)
Clinuvel is an ASX-listed global pharmaceutical company that develops and commercializes treatments for various systematic, metabolic, genetic, and acute disorders. In addition, it develops various healthcare solutions for the general population.
The primary product of Clinuvel is SCENESSE which is used in the treatment of a range of skin disorders.
The current market capitalization of the company is $950,654,903.
Stock Information
The last closing price of the stock was $19.24. The current earnings per share are $0.471. The stock is trading at a very attractive valuation as it has corrected around 52.79% in the last 1 year. However, buying momentum is building up as the stock has recovered 10.83% in the last 1 week.
In the last financial reports, the firm reported revenue of $67 million (up 38%) and a profit of $21 million (up 15.6%). The company is experiencing a major pick in its commercial operations and demands. The company is pursuing several R&D projects which would add future value to the stock. Overall, Clinuvel is a strong investment-grade stock.
4. Neuren (ASX: NEU)
Neuren is an ASX-listed biopharmaceutical company that focuses mainly on neurological disorders, neurodevelopment, neurodegenerative disorders, brain injury, etc. The company is currently developing two drugs for several serious neurological disorders in early childhood, for which there are no drugs currently.
In a major development for the company, the US partner of Nauren submitted an application to US FDA for trofinetide, a drug that treats Rett syndrome in adults and pediatric patients aged two years and older. This development has the potential to be a great commercial success for the company.
The current market capitalization of the company is s $806,180,326.
Stock Information
The last closing price of the stock was $6.40. The stock currently has great momentum. It has appreciated by 175.86% in the last 1 year. Also, it has outperformed the healthcare sector by 186.75% in the last 1 year. The great momentum and outperformance show the high level of demand for the stock driven by a strong future potential.
5. Probiotec Limited (ASX: PBP)
Probiotec is an ASX-listed company that deals with the development, manufacturing, and sale of pharmaceutical, nutraceutical, and consumer health products. It offers contract manufacturing and packing services. It has world-class facilities for developing and contract manufacturing pharmaceutical products in locations across Australia.
The current market capitalization of the company is $177,285,025.
Stock Information
The last closing price of the stock was $2.18. The current earnings per share of the stock are $0.106. The stock has remained mostly flat in the last 1 year. It is currently trading 0.91% down compared to 1 year before. However, the stock has outperformed the sector by around 10% in the same period. It has also outperformed the broader ASX 200 index by 9.73% in the last 1 year.
Read more - https://veye.com.au/article/top-5-asx-200-healthcare-stocks-for-2022
0 notes
Link
There are so many factors investor needs to follow when they search for growth stocks. Number of equities get scanned for key financial and quality factory.
0 notes
Link
View today's TLS share price, options, bonds, hybrids and warrants. View announcements, advanced pricing charts, trading status, fundamentals
0 notes
Text
Brainchip Holdings Ltd (BRN) Company Overview and Analysis
Read More: https://bit.ly/3BIvUHv
0 notes
Text
Fintip: Master the ASX Sharemarket Game with the Ultimate Trading
Fintip is an exhilarating ASX Sharemarket Game that offers an immersive experience for both beginners and seasoned traders. With Fintip, you can embark on a virtual journey of investing in the stock market, honing your trading skills, and competing with others to achieve financial success.
0 notes
Text
Enhancing Your ASX Sharemarket Game Experience with Trading - Fintip
Gain valuable insights into the complexities of the ASX share market game as you navigate real-time market data, track your portfolio performance, and make strategic trading decisions. Fintip's gamified approach makes learning about the share market engaging and fun, empowering you to sharpen your trading skills and prepare for real-world investing. Immerse yourself in the world of virtual trading and unlock your potential with Fintip.
0 notes
Text
Fintip: Empowering Investors on the ASX Australian Stock Exchange
Fintip is a game-changing platform designed to empower investors on the ASX Australian Stock Exchange. With its user-friendly interface and powerful analytical tools, Fintip provides individuals with the insights and information they need to make informed investment decisions. Discover the power of Fintip and unlock your potential in the Australian stock market.
0 notes
Text
ASX Australian Stock Exchange - Fintip: Empowering Investors with Cutting-Edge Financial Technology
Discover the powerful synergy between the ASX Australian Stock Exchange and Fintip, a revolutionary financial technology platform. Fintip combines state-of-the-art data analytics and intuitive investment tools to empower investors with real-time market insights, comprehensive portfolio management, and strategic decision-making capabilities. For more detail, please join with the link: https://fintip.com.au/asx-australian-stock-exchange/
0 notes
Text
Invest in ASX Australian Stock Exchange - Fintip
Fintip is a leading investment platform that empowers individuals to explore and invest in the (ASX)Australian Stock Exchange. With its user-friendly interface and comprehensive range of financial tools, Fintip makes it easy for both seasoned investors and newcomers to navigate the world of stocks and shares and seize opportunities in the dynamic ASX market. Follow the link for more info: https://fintip.com.au/
0 notes
Text
Dividend investing is an approach to invest in stocks, primarily to receive a consistent income in the form of dividends. Dividends are payments that a company makes to its shareholders from the pool of its net profits.
1 note
·
View note
Link
Penny stocks which come under the bracket of $1 per share price sometimes provide windfall gains to its holders. For investors who are ready to take high risk, penny stocks can be a better option to invest in. Sometimes, penny stock offers the quickest way to make money because of the high-risk, high-reward factor. Therefore, a penny stock investment backed by good research can provide investors with more than 2X returns in a month.
1 note
·
View note
Text
3 Cannabis stocks to grab before they start moving
Creso Pharma, Cann Group, AusCann Group: http://bit.ly/396f6ye
CPH, AC8, CAN
1 note
·
View note
Link
Having weathered a pandemic-scarred year, the Australian economy seems to be bouncing back in style with a V-shaped recovery already bumping up the housing market and retail spending. As per the Australian Bureau of Statistics (ABS) figures, GDP marked an uptick of 3.1% during the December quarter, which is significantly higher than the past projections.
The faster-than-anticipated recovery seems to boost the country’s financial market scenario, with investors vying to make up for their last year’s losses through investment in small-cap stocks. Small-cap shares have low market capitalisation and offer higher growth potential. Owing to their higher returns, the risk associated with such stocks are also high.
1 note
·
View note
Link
Access detailed information about the BPH Energy Ltd (BPH) Share including Price, Charts, Technical Analysis, Historical data, BPH Energy Ltd Reports and more
0 notes
Last Seen Blogs
aedkartha
Untitled
scribf1nite
Gengar Blog(co-owned By Jevil&Niko)
hotgirlskpop
女神
thecarlarossi
THE GOSPEL OF ROSSIANITY